Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 (CYP2C9) Kits ELISA

CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes. De plus, nous expédions CYP2C9 Anticorps (74) et CYP2C9 Protéines (5) et beaucoup plus de produits pour cette protéine.

list all ELISA KIts Gène GeneID UniProt
CYP2C9 1559 P11712
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne

Top CYP2C9 Kits ELISA sur

Showing 6 out of 14 products:

Catalogue No. Reactivité Sensibilité Gamme Images Quantité Livraison Prix Détails
Humain 5.8 pg/mL 23.5-1500 pg/mL Typical standard curve 96 Tests 15 to 18 Days
Rat 0.124 ng/mL 0.31 ng/mL - 20 ng/mL 96 Tests 13 to 16 Days
Humain < 0.236 ng/mL 0.625 ng/mL - 40 ng/mL   96 Tests 11 to 18 Days
Rat < 0.124 ng/mL 0.312 ng/mL - 20 ng/mL   96 Tests 11 to 18 Days
  100 Tests 2 to 3 Days
  100 Tests 2 to 3 Days

Plus Kits ELISA pour CYP2C9 partenaires d'interaction

Human Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 (CYP2C9) interaction partners

  1. These findings report single nucleotide polymorphisms in the human CYP2C9 genes, CYP2C9*2 and CYP2C9*3, exert a direct protective role in tumorigenesis by impairing EET biosynthesis.

  2. Of the 41 patients included in the analysis, age, VKORC1, CYP2C9*2/*3 and CYP3A4*1B were statistically significantly associated with dose requirement.

  3. allele frequency distributions for CYP2C19 and CYP2C9 variants among the Tunisian population are comparable to those among European and Middle Eastern populations; identified a common haplotype in the Tunisian population carrying the CYP2C19*17, CYP2C9*1 alleles, representing a haplotype encoding efficient metabolism of drugs that are substrates for CYP2C enzymes

  4. The presence of mutations in VKORC1 or CYP2C9 is associated with increased risk of bleeding in patients with BCS on warfarin.

  5. The presence of CYP2C9 allelic variants (rs1799853 and rs1057910) in the family members suffering from idiopathic pulmonary fibrosis (IPF) indicate a previously unsuspected link between these variants and IPF.

  6. The effect of CKD on CYP1A2, CYP2C9, and CYP2C19 was variable and modest compared to CYP2C8 and OATP.

  7. Polymorphic alleles of CYP2C9 or AG/AA haplotype had twice the odds of bleeding (cOR=2.14 and 2.44 respectively) relative to those with wild CYP2C9 allele or GG haplotype.

  8. Type 2 diabetic patients with mutant CYP2C9 polymorphism may show different antidiabetic drug metabolism compared to the wild-type allele.

  9. The in vitro studies of Pristimerin (PTM) with CYP isoforms indicate that PTM has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, 3A4 and 2C9.

  10. Molecular dynamics simulations performed for the active species of the enzyme (heme in the Compound I state), in the apo or substrate-bound state, and binding energy analyses gave insights into altered protein structure and dynamics involved in the defective drug metabolism of human allelic variant CYP2C9*30 (A477T).

  11. Lower expression of CYP2C9 was associated with better overall survival and disease-free survival in Hepatocellular carcinoma tumor samples.

  12. In the villous trophoblast, CYP2C8 was the most abundant protein. Its expression is higher than the CYP2C9 and CYP2J2 in the cytotrophoblast in the embryonic stage of development and remains higher in syncytiotrophoblast of term placenta.

  13. A significant association between CYP2C9*3 and phenytoin-induced Stevens-Johnson syndrome was identified, especially in a Thai population (Meta-Analysis)

  14. In this study, we showed that patients with VKORC1-1639GA and CYP2C9*1/*1 alleles have lower sensitivity for warfarin than those with VKORC1-1639AA and CYP2C9*1/*1 alleles.

  15. Enzyme phenotyping with correlation analysis confirmed the predominant role of CYP2C9 in the biotransformation of siponimod and demonstrated the functional consequence of CYP2C9 genetic polymorphisms and fluconazole on siponimod metabolism.

  16. Comparisons of pharmacokinetics of 25 substrates CYP2C9, CYP2C19, or CYP2D6 in healthy Chinese and European subjects (classified with same enzyme activity) suggest that, for most substrates, limited interethnic pharmacokinetic differences exist (according to the databases used in this study). (CYP2C19 = cytochrome P450 family 2 subfamily C member 19; CYP2D6 = cytochrome P450 family 2 subfamily D member 6)

  17. genetic association studies in population in Scotland: data suggest, in type 2 diabetes treated with sulfonylureas, 2 SNPs in CYP2C9 (CYP2C9*2, R144C, rs1799853; CYP2C9*3, I359L, rs1057910) are associated with drug-induced hypoglycemia; an SNP in POR (POR*28, A503V, rs1057868) is associated with better response to sulfonylureas. (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; POR = cytochrome p450 oxidoreductase)

  18. The plasma S-warfarin (Cp(S)) time courses following the genotype-based dosing algorithms simulated using the PPK estimates showed African Americans with CYP2C9*1/*1 and any of the VKORC1 genotypes would have an average Cp(S) at steady state 1.5-1.8 times higher than in Asians and whites.

  19. The final regression models for White and Black patients (Fig. 1) included age, weight, prosthetic valves, amiodarone use, CYP2C9*3, and VKORC1 3673 G>A genotypes as covariates, whereas possession of CYP2C9*2 and simvastatin use were retained in the final model for White, but not Black patients.

  20. The present study confirms the variable distribution of CYP2C8 (*2 and *3) and CYP2C9 (*2 and *3) allelic polymorphisms among South Indian diabetic populations.

CYP2C9 profil antigène

Antigen Summary

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.

Gene names and symbols associated with CYP2C9

  • cytochrome P450 family 2 subfamily C member 9 (CYP2C9) anticorps
  • CPC9 anticorps
  • CYP2C anticorps
  • CYP2C10 anticorps
  • CYPIIC9 anticorps
  • P450IIC9 anticorps

Protein level used designations for CYP2C9

cytochrome P-450 S-mephenytoin 4-hydroxylase , cytochrome P-450MP , cytochrome P450 2C9 , cytochrome P450 PB-1 , flavoprotein-linked monooxygenase , microsomal monooxygenase , xenobiotic monooxygenase

1559 Homo sapiens
Fournisseurs de qualité sélectionnés pour CYP2C9 (CYP2C9) Kits ELISA
Avez-vous cherché autre chose?